Vaxcyte, Inc.
No enriched coverage for $PCVX in the last 7 days.
Baupost Group, via its 13F filed Aug. 13, 2026, reported exiting all of its Vaxcyte (PCVX) shares during the June quarter, cutting 800,000 shares to zero, a reported -$46.5M change. It also exited Willis Towers Watson (WTW), reducing 893,126 shares to zero, -$259.6M. The article cites Vaxcyte’s pre-revenue status and upcoming OPUS-1 Phase 3 topline in Q4 2026.
Mizuho updated its U.S. healthcare “Top Picks” list for 2026, citing seven companies across biotech, medical devices, and healthcare services. Highlights include Eyepoint Pharmaceuticals (Duravyu Phase 3 data expected Aug 2026), Vaxcyte (PCV Phase 3 OPUS-1 data in Q4 2026), Erasca (raised about $632.5M in an offering), and Arcutis (Zoryve guidance $480M-$495M for 2026).
Dhaliwal Harpreet S. (Chief Technical Ops Officer) sold 17,000 shares of Vaxcyte, Inc. (PCVX) at $55.00 ($0.94M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
Recent PCVX coverage spans insider activity, financial news and sector analysis.
In the last 30 days, PCVX insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($1.6M). The most active reporter was Wassil Jim, CHIEF OPERATING OFFICER, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The disclosed exit is a sentiment and positioning signal for PCVX into a binary Phase 3 catalyst, but it is not new clinical or financial guidance.
The key trade driver is the Q4 2026 OPUS-1 read-through and the expansion of the pipeline with VAX-A1 first dosing.
This is a routine, pre-arranged insider sale disclosure, not a fundamental company update.
Near-term catalyst is OPUS-1 topline in Q4 2026, with additional Phase 3 readouts in H1 2027 supporting a potential BLA submission and U.S. launch path.
Routine 10b5-1 insider selling by the CFO, with no accompanying operational or guidance change disclosed.
alphai scores every news story that mentions PCVX with an AI model for sentiment and relevance, and aggregates insider trades from Vaxcyte, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Baupost Group, via its 13F filed Aug. 13, 2026, reported exiting all of its Vaxcyte (PCVX) shares during the June quarter, cutting 800,000 shares to zero, a reported -$46.5M change. It also exited Willis Towers Watson (WTW), reducing 893,126 shares to zero, -$259.6M. The article cites Vaxcyte’s pre-revenue status and upcoming OPUS-1 Phase 3 topline in Q4 2026.
6 min readMizuho updated its U.S. healthcare “Top Picks” list for 2026, citing seven companies across biotech, medical devices, and healthcare services. Highlights include Eyepoint Pharmaceuticals (Duravyu Phase 3 data expected Aug 2026), Vaxcyte (PCV Phase 3 OPUS-1 data in Q4 2026), Erasca (raised about $632.5M in an offering), and Arcutis (Zoryve guidance $480M-$495M for 2026).
5 min readDhaliwal Harpreet S. (Chief Technical Ops Officer) sold 17,000 shares of Vaxcyte, Inc. (PCVX) at $55.00 ($0.94M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
1 min readVaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half
6 min readGUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares of Vaxcyte, Inc. (PCVX) at an average of $53.89 ($53.76–$54.18, $0.54M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
2 min readPICKERING GRANT (CHIEF EXECUTIVE OFFICER) sold 16,198 shares of Vaxcyte, Inc. (PCVX) at an average of $55.63 ($55.52–$55.93, $0.90M total) across 2 trades on 2026-07-27 under a Rule 10b5-1 trading plan.
2 min readVaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pcvx-20260713 0001649094 FALSE 825 Industrial Road Suite 300 San Carlos California 0001649094 2026-07-13 2026-07-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________________________ FORM 8-K _____________________________________
2 min readMizuho, via Investing.com, highlighted seven U.S. healthcare stocks for growth, citing clinical catalysts and operational updates. Price targets and ratings include EYPT $36, PCVX $163, ERAS $26, ARQT $35, LNTH $115, EHC $134, and SOLV $100. Key items include EYPT Phase 3 data in Aug 2026, PCVX Phase 3 in 4Q 2026, and LNTH PDUFA mid-Aug 2026.
4 min readGUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares of Vaxcyte, Inc. (PCVX) at an average of $57.28 ($57.16–$57.76, $0.57M total) across 2 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
1 min readVaxcyte (PCVX) updated investors on an early-stage trial of its VAX-A1 vaccine for Group A strep, testing three dose levels vs placebo in healthy young adults to assess safety, tolerability, and immunogenicity. Mizuho Securities reiterated a Buy rating and set a $163 price target, citing about 180% upside.
3 min read
